Argatroban
Argatroban (argatroban) is a small molecule pharmaceutical. Argatroban was first approved as Argatroban on 2000-06-30. It is used to treat thrombocytopenia and thromboembolism in the USA. The pharmaceutical is active against prothrombin.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Argatroban (discontinued: Argatroban)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Argatroban
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ARGATROBAN IN SODIUM CHLORIDE | Accord Healthcare | N-212035 RX | 2021-06-07 | 1 products, RLD, RS |
| ARGATROBAN IN SODIUM CHLORIDE | Eugia Pharma Specialties | N-209552 RX | 2018-11-27 | 1 products |
| ARGATROBAN | Fresenius Kabi | N-201811 RX | 2015-03-23 | 1 products |
| ARGATROBAN | Hikma Pharmaceuticals | N-203049 RX | 2012-01-05 | 2 products, RLD, RS |
| ARGATROBAN IN SODIUM CHLORIDE | Sandoz | N-022485 RX | 2011-05-09 | 1 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| argatroban | New Drug Application | 2024-10-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| thromboembolism | HP_0001907 | D013923 | — |
| thrombocytopenia | HP_0001873 | D013921 | D69.6 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J0883 | Injection, argatroban, 1 mg (for non-esrd use) |
| J0884 | Injection, argatroban, 1 mg (for esrd on dialysis) |
| J0891 | Injection, argatroban (accord), not therapeutically equivalent to j0883, 1 mg (for non-esrd use) |
| J0892 | Injection, argatroban (accord), not therapeutically equivalent to j0884, 1 mg (for esrd on dialysis) |
| J0898 | Injection, argatroban (auromedics), not therapeutically equivalent to j0883, 1 mg (for non-esrd use) |
| J0899 | Injection, argatroban (auromedics), not therapeutically equivalent to j0884, 1 mg (for esrd on dialysis) |
Clinical
No data
Drug
General
| Drug common name | Argatroban |
| INN | argatroban |
| Description | Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it. In 2012, it was approved by the MHRA in the UK for anticoagulation in patients with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.
|
| Classification | Small molecule |
| Drug class | antithrombotics (thromboxane A2 receptor antagonists) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 74863-84-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1166 |
| ChEBI ID | — |
| PubChem CID | 440542 |
| DrugBank | DB00278 |
| UNII ID | OCY3U280Y3 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use